Lotte Biologics to Raise 240.5 Billion KRW in Capital Increase for Acquisition of US Factory
[Asia Economy Reporter Park Soyeon] Lotte Biologics announced on the 20th that it has decided to conduct a rights offering worth 240.5 billion KRW to raise funds for the acquisition of its factory in Syracuse, USA.
The purpose of the rights offering is to raise funds for operating expenses of its US subsidiary, Lotte Biologics USA (20.54 billion KRW), and for the acquisition of securities of other corporations (219.96 billion KRW).
Hot Picks Today
As Samsung Falters, Chinese DRAM Surges: CXMT Returns to Profit in Just One Year
- "Most Americans Didn't Want This"... Americans Lose 60 Trillion Won to Soaring Fuel Costs
- Man in His 30s Dies After Assaulting Father and Falling from Yongin Apartment
- Samsung Union Member Sparks Controversy With Telegram Post: "Let's Push KOSPI Down to 5,000"
- "Why Make Things Like This?" Foreign Media Highlights Bizarre Phenomenon Spreading in Korea
The first subscription for operating funds will be on December 4, and the second subscription will be on December 20.
This content was produced with the assistance of AI translation services.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
